A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout
Information source: Merck
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Gout
Intervention: MK0663; etoricoxib / Duration of Treatment: 5 Days (Drug); Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Merck Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck
Summary
A study to evaluate the effects of etoricoxib and indomethacin in the treatment of acute
gout.
Clinical Details
Official title: A Randomized, Double-Blind, Active-Comparator-Controlled 5-Day Trial of the Effect of Etoricoxib 120 Mg Versus Indomethacin 150 Mg in the Treatment of Acute Gout
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: Patient assessment of pain (0- to 4- Likert scale)
Secondary outcome: Patient Global Assessment of Response to Therapy (0- to 4- point scale)Investigator Global Assessment of Response to Therapy (0- to 4- point scale) Tenderness of the study joint (0- to 3-point scale) Swelling of the study joint (0- to 3-point scale)
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Males or females at least 18 years of age who have acute gout.
Locations and Contacts
Merck Sharp & Dohme (China) Ltd., Beijing 100738, China
Additional Information
Starting date: January 2005
Last updated: September 7, 2006
|
